Studies in cell lines and primary cells have revealed that when overexpressed, all pro-survival BCL-2 family members, BCL-2, BCL-XL, BCL-W, A1 and MCL-1, are capable of inhibiting the mitochondrial apoptotic pathway.^[@bib1]^ Transgenic expression (using the immunoglobulin heavy chain gene enhancer, *Eμ*, or the *Vav* gene promoter, *VavP*) of BCL-2, BCL-XL or MCL-1 results in increased abundance of immature, transitional and mature B-cell subsets,^[@bib2],\ [@bib3],\ [@bib4]^ although the marginal zone B cells were not affected by excess BCL-2 or BCL-XL.^[@bib5]^ A detailed analysis of the individual and overlapping contributions of pro-survival BCL-2 family members to normal lymphocyte persistence *in vivo*, however, has been hampered by their necessity during embryonic development. Complete loss of MCL-1 in mice results in embryonic lethality prior to day 3.5,^[@bib6]^ whereas BCL-XL-deficient mice die around embryonic day 14.^[@bib7]^ BCL-2-deficient mice, although born at the expected frequency, succumb to polycystic kidney disease, which commences during embryogenesis.^[@bib8],\ [@bib9]^ The relevance of BCL-W expression to lymphocyte differentiation appears limited, as lymphoid development in BCL-W-deficient mice is normal.^[@bib10]^ This is probably due to the low expression of BCL-W in normal as well as malignant lymphoid cells.^[@bib11]^ The generation of A1-deficient mice has proven difficult owing to quadruplication at the gene locus in mice, but transgenic RNA interference-mediated knockdown of A1 in mice revealed a role for A1 in the maintenance of mature follicular B cells.^[@bib12]^ The recent use of the BH3-mimetic compounds (ABT-263/Navitoclax: inhibits BCL-2, BCL-XL and BCL-W and ABT-199/Venetoclax: inhibits BCL-2) to treat B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma,^[@bib13],\ [@bib14]^ and programs to develop MCL-1-specific BH3-mimetics, suggest that the detailed analysis of the role of individual BCL-2 family proteins in the maintenance of healthy B cells should be useful in aligning the use of such drugs with particular disorders and in predicting damage to normal B-cell subsets imposed by such therapies.

We have previously shown that, with the appropriate genetic configuration, the *Mcl1* gene can be efficiently deleted in the B-cell lineage *in vivo.*^[@bib15],\ [@bib16]^ In the current study we used this strategy to delete the *Mcl1* and/or *Bclx* genes in an inducible fashion, with and without concomitant treatment with the BH3-mimetic compound ABT-737, to assess the individual and overlapping roles of these pro-survival BCL-2 family members in the maintenance of different B-cell subsets. From these experiments, we have learnt that BCL-XL is of only limited importance in B-cell development, that MCL-1 is required at multiple stages and that BCL-2, the main target of ABT-737 in mice *in vivo*,^[@bib17],\ [@bib18]^ promotes survival of some terminally differentiated Blimp-1^hi^ PC, in addition to promoting survival of mature follicular and recirculating B cells. Moreover, we found that deletion of one allele of *Mcl1* sensitizes transitional and mature B cells to loss of BCL-XL. Furthermore, deletion of both alleles of *Mcl1* greatly sensitized established plasma cells (PC) to treatment with ABT-737, even though the total PC pool in wild-type mice was not significantly affected by exposure to this drug.^[@bib19]^

Results
=======

The importance of MCL-1 for B-lymphocyte development in mice has been demonstrated by others using CD19-Cre-mediated deletion of *Mcl1*^*fl*^ alleles. These studies revealed a significant reduction in all B-cell subsets from the early pro-B-cell stage onwards,^[@bib20]^ this being the stage of Cre-recombinase expression and thus deletion of *Mcl1*^*fl*^. These experiments, however, could not reveal a role for MCL-1 beyond the pro-B-cell stage as differentiation was halted at this point. To determine if there is differentiation stage-specific sensitivity to *Mcl1* deletion in the B-cell lineage specifically, we used a mouse model in which *Mcl1*^*fl*^ could be efficiently deleted in established B-cell populations of adult mice by delivery of tamoxifen to activate a conditional Cre^ERT2^ recombinase.^[@bib16]^ Deletion of both *Mcl1*^*fl*^ alleles in this way rapidly reduced the absolute number of cells in transitional and mature B-cell subsets in the spleen and bone marrow (BM) ([Figures 1a--d](#fig1){ref-type="fig"}). The impact of *Mcl1*^*fl*^ deletion in PC in this setting has been previously reported^[@bib16]^ and the fold difference in PC number after tamoxifen-mediated *Mcl1*^*fl*^ deletion is included ([Figure 1d](#fig1){ref-type="fig"}).

To determine the contribution of BCL-XL to the sustained survival of B-cell subsets, we created BM chimeric mice in which *Bclx*^*fl*^ alleles could be inducibly deleted in the B-cell lineage.^[@bib16]^ Loss of BCL-XL significantly reduced only the BM immature B-cell population ([Figures 2a and b](#fig2){ref-type="fig"}). Because of the relatively modest impact of *Bclx*^*fl*^ deletion, we next examined the consequences of combined inducible deletion of both alleles of *Bclx*^*fl*^ plus one allele of *Mcl1*^*fl*^. In addition to a reduction in the numbers of immature B cells caused by loss of BCL-XL expression, additional deletion of one *Mcl1*^*fl*^ allele also significantly reduced the numbers of transitional B cells in the BM as well as T1, follicular B and PC in the spleen ([Figures 2c and d](#fig2){ref-type="fig"}). The fold differences shown are calculated comparing *Mcl1*^*fl/+*^*Bclx*^*fl/fl*^ER^T2^Cre with *Mcl1*^*fl/+*^*Bclx*^*+l+*^ER^T2^Cre, thus revealing the impact of *Bclx* deletion in a setting in which MCL-1 expression is reduced with 50% ([Figure 2d](#fig2){ref-type="fig"}).

As BCL-XL is mainly important for cell survival during early B-cell development, *Bclx* gene expression was measured and related to gene expression of *Mcl1*, *Bcl2* and *A1*. This analysis revealed that, contrary to expression of *Mcl1* and *Bcl2*, *Bclx* transcription peaks early during B-cell development and is highest in immature B cells ([Figure 3](#fig3){ref-type="fig"}). Expression of both *Mcl1* and *Bcl2* peaks in terminally differentiated PC, whereas expression of *A1* is relatively low in immature B cells and PC but high in T1 and T2 transitional cells and mature marginal zone and follicular B cells ([Figure 3](#fig3){ref-type="fig"}).

ABT-737 potently binds to BCL-2, BCL-XL and BCL-W in Biacore assays, but has a clear preference for blocking BCL-2 in living cells in culture and within the whole mouse.^[@bib17],\ [@bib18]^ Thus, its effects on cell survival *in vivo* can mainly be attributed to inhibition of BCL-2. ABT-737 was chosen for reasons of cost and availability, and when administered by intraperitoneal injection, becomes available to all relevant organs.^[@bib19]^ ABT-737 has a very similar binding specificity and affinity as the BH3-mimetic ABT-263/Navitoclax that has improved bioavailability.^[@bib21]^ Treatment of mice with ABT-737 promotes apoptosis of mature follicular B cells in the spleen and recirculating B cells in the BM,^[@bib19],\ [@bib22]^ it also affects the survival of newly generated PC *en route* to the BM, but does not markedly affect preexisting PCs.^[@bib19]^ We examined the impact of ABT-737 on PC in more detail and found that the total PC population in the BM, but not the spleen, was mildly, but significantly, reduced upon treatment ([Figures 4a and b](#fig4){ref-type="fig"}). In addition, we found that mature follicular and recirculating B cells were strongly reduced after treatment, as expected from previous studies. We also observed a significant reduction in the numbers of marginal zone B cells and transitional B cells in the BM ([Figures 4a and b](#fig4){ref-type="fig"}). Next, we compared short-lived (Blimp-1^int^) with long-lived (Blimp-1^hi^) PC for sensitivity to ABT-737 by treating Blimp-1-GFP reporter mice (in which GFP is expressed from the gene encoding Blimp-1 (*Prdm1*^GFP^))^[@bib23]^ with this drug. Interestingly, we observed that in both the spleen and BM, only the Blimp-1^hi^ PC were affected by ABT-737 treatment ([Figures 4c and d](#fig4){ref-type="fig"}). As, in contrast to the spleen, the majority of PC in the BM are long-lived Blimp-1^hi^ PC,^[@bib23]^ these observations are in line with the results on the total PC population in [Figure 4a](#fig4){ref-type="fig"}.

We have shown previously that MCL-1 expression is essential for PC survival and that signaling through the TNF receptor (TNFR) family member BCMA promotes *Mcl1* transcription in BM PC.^[@bib16]^ In fact, we have shown that *Mcl1* gene expression was 3.4-fold lower in *Bcma*^−/−^ BM PC as compared with wild-type BM PC.^[@bib16]^ Mice deficient for BCMA in haematopoietic cells were treated with ABT-737 as before and the impact on PC maintenance was measured. Although PC numbers in the BM were reduced in *Bcma*^−/−^ mice,^[@bib16],\ [@bib24]^ those PC that survive in the absence of BCMA-signaling remained as sensitive to treatment with ABT-737 as do those BM PC that survive in its presence ([Figure 5](#fig5){ref-type="fig"}). These results suggest the existence of non-overlapping roles between MCL-1, albeit reduced in BCMA-deficient BM PC, and BCL-2, the main target of ABT-737 in mice.^[@bib17],\ [@bib18]^ Therefore, we further tested the combinatorial dependence of MCL-1 and BCL-2 expression on PC survival. The combined impact of ABT-737 treatment with deletion of both *Mcl1*^*fl*^alleles was examined. Treatment with ABT-737 in the absence of MCL-1 revealed a similar impact on follicular and recirculating B cells as compared with ABT-737 treatment in wild-type mice ([Figures 6a and b](#fig6){ref-type="fig"}). However, ABT-737 treatment in the absence of MCL-1 greatly augmented the reduction in PC populations in both the spleen and BM owing to MCL-1 ([Figures 6a and b](#fig6){ref-type="fig"}).

To complement our *in vivo* studies, we examined dependence on BCL-2, BCL-XL or MCL-1 expression using novel and highly specific BH3-mimetics with murine splenocytes and BM cells in culture. Identical to *Bclx* gene deletion experiments *in vivo* ([Figures 2a and b](#fig2){ref-type="fig"}), treatment with the BCL-XL-specific inhibitor, A-1155463,^[@bib25]^ only reduced the viability of immature B cells ([Figure 7a](#fig7){ref-type="fig"}). Sensitivity to the BCL-2-specific inhibitor ABT-199/Venetoclax^[@bib13]^ was comparable to our observations with *in vivo* experiments using ABT-737 ([Figures 4a and b](#fig4){ref-type="fig"}), promoting apoptosis of mature marginal zone, follicular and recirculating B cells. In addition, we observed impaired survival of transitional type 2 cells from the spleen ([Figure 7b](#fig7){ref-type="fig"}). The latter was not observed in our *in vivo* experiments with ABT-737, but was previously described in an identical experimental set-up using ABT-199.^[@bib26]^ As expected from our experiments in [Figures 4C and D](#fig4){ref-type="fig"}, ABT-199 promoted apoptosis of fully differentiated PC, whereas early plasmablasts (PB, comparable to Blimp-intermediate PC) were unaffected by treatment with this drug ([Figure 7b](#fig7){ref-type="fig"}). Next we tested the role of MCL-1 in survival of B-cell subsets using the MCL-1 inhibitor A-1210477. Although A-1210477 is highly specific for MCL-1, it lacks potency to reveal subtle differences in MCL-1 dependence.^[@bib27]^ In line with our gene deletion experiments presented in [Figure 1](#fig1){ref-type="fig"} and previous findings,^[@bib16]^ we observed that the transitional as well as mature B-cell- and PC-subsets, but not immature B cells, were sensitive to treatment with this drug ([Figure 7c](#fig7){ref-type="fig"}). In contrast to our *in vivo* experiments, we found that transitional type 2 cells in the spleen were sensitive, but transitional B cells from the BM were insensitive to A-1210477. The differential dependence on BCL-2 or MCL-1 expression in transitional B cells from the BM or transitional type 2 B cells from the spleen between our *in vitro* or *in vivo* models may be possible owing to the potency of the BH3-mimetics or the role of the protective microenvironment *in vivo*.

Discussion
==========

Selective targeting of pro-survival BCL-2 family members can provide an attractive strategy for treating B-cell malignancies, either as single treatment or in combination with additional treatment modalities. This is exemplified by the recent discovery and use of the BCL-2-specific inhibitor ABT-199 (Venetoclax).^[@bib13]^ Venetoclax has proven successful in multiple clinical trials and is a promising new treatment for CLL, certain non-Hodgkin lymphomas and other malignancies.^[@bib14],\ [@bib28]^ Its predecessor, Navitoclax/ABT-263 (the orally bioavailable form of ABT-737), targets not only BCL-2, but also BCL-XL and BCL-W. As expression of BCL-XL is required for maintenance of platelets, Navitoclax evoked severe thrombocytopenia in clinical trials as an unwanted side-effect.^[@bib28]^ The main target of ABT-737 in mice, however, was shown to be BCL-2 and not BCL-XL or BCL-W.^[@bib17],\ [@bib18]^ In addition to BCL-2 inhibition, novel drugs have been described that more specifically inhibit only BCL-XL (WEHI-539 and A-1155463)^[@bib25],\ [@bib29]^ or MCL-1 (A-1210477).^[@bib27]^ As various tumor types depend on MCL-1 or BCL-XL expression,^[@bib14]^ it is only a matter of time before specific inhibitors targeting these molecules will also find their way into the clinic. However, the importance of MCL-1, BCL-2 and BCL-XL expression for the survival of healthy cell subsets *in vivo* is still incompletely understood. Thus, treatment with these specific inhibitors used alone or in combination may elicit unwanted side-effects, as seen with the impact of BCL-XL inhibition on platelets. A thorough understanding of the effects of BH3-mimetic drugs on normal cells should aid the development of a tailored treatment design that minimizes side-effects. Conversely, knowing which cell subsets are sensitive to the different inhibitors may provide clues on how to treat their malignant counterparts.

To assess the individual and overlapping roles of MCL-1, BCL-2 and BCL-XL in the maintenance of different B-cell subsets, we examined mice where the *Mcl1* and/or *Bclx* genes were inducibly deleted in the B-cell lineage. This was performed in combination with ABT-737 treatment. Our findings demonstrate a reliance on MCL-1 expression throughout the B-cell lineage and indicate that even short-term loss of MCL-1 expression -- for \<2 days -- will deplete B-cell subsets at multiple stages of development ([Figures 1](#fig1){ref-type="fig"} and [7c](#fig7){ref-type="fig"}). In contrast, loss of BCL-XL expression, even up to 4 days, only affects the maintenance of immature B cells. The specific dependence of this B-cell subset on expression of BCL-XL was confirmed using the BCL-XL-specific inhibitor, A-1155463 ([Figure 7a](#fig7){ref-type="fig"}). Hemizygous deletion of *Mcl1* did, however, sensitize transitional B cells and splenic PC to loss of BCL-XL ([Figure 2](#fig2){ref-type="fig"}). Previous reports have shown that treatment of mice with ABT-737 results in a decrease of follicular and recirculating mature B cells.^[@bib19],\ [@bib22]^ It inhibited the induction of newly generated PC, but left preexisting PC intact.^[@bib19]^ We show here that also long-lived terminally differentiated (Blimp-1^hi^) PC, but not short-lived Blimp-1^int^ PC, are reduced after treatment with ABT-737 ([Figure 4](#fig4){ref-type="fig"}). In the above-mentioned experiments ABT-737 was chosen to study the role of BCL-2, its main *in vivo* target, for reasons of cost and availability. We did, however, also use the BCL-2-specific BH3-mimetic ABT-199 on isolated BM and splenic B cells in culture. These experiments confirmed to a large extend our *in vivo* findings when using ABT-737, with mature marginal zone, follicular and recirculating B cells sensitive to BCL-2 inhibition ([Figure 7b](#fig7){ref-type="fig"}). We also confirmed our *in vivo* findings, proving that long-lived (B220^low^ or Blimp-1^hi^) PC depend on BCL-2 expression, whereas recently generated, or short-lived (B220^hi^ or Blimp-1^int^) PC do not ([Figure 7b](#fig7){ref-type="fig"}). The notion that mainly Blimp-1^hi^ PC are sensitive to this treatment correlates with previous findings showing that *Bcl2* expression is higher in these cells compared to Blimp-1^int^ PC.^[@bib16]^ As PC seem to be affected both by deletion of *Mcl1* and treatment with ABT-737, the combined impact on cell survival was examined. BCMA, a TNFR family member expressed specifically on PC, promotes survival of BM PC via transcriptional induction of *Mcl1* and, as a consequence, the number of BM PC in *Bcma*^−/−^ mice is significantly reduced.^[@bib16],\ [@bib24]^ ABT-737 treatment of mice reconstituted with *Bcma*^−/−^ BM showed a similar fold reduction in the numbers of BM PC as seen in wild-type mice treated with ABT-737 ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). This means that reduced MCL-1 expression, caused by the absence of BCMA-signaling, and inhibition of BCL-2 with ABT-737 have additive effects on the reduction of BM PC. The combined effects of BCL-2 inhibition and reduced MCL-1 expression were further examined by treating mice with ABT-737 together with genetically deleting one or both alleles of *Mcl1*. These experiments revealed that B-cell populations in mice with hemizygous deletion of *Mcl1* are equally sensitive to treatment with ABT-737 compared with wild-type mice (data not shown). However, PC in mice with homozygous deletion of *Mcl1* are strikingly sensitive to ABT-737 ([Figure 6](#fig6){ref-type="fig"}). These synergistic effects between inhibited BCL-2 and loss of MCL-1 expression seem to be specific for PC and opens up a potential therapeutic strategy for deletion of auto-reactive or malignant PC in patients. This finding does, however, argue that the reduction in MCL-1 expression needs to be substantial (more than 3.4-fold based on experiments with *Bcma*^*−/−*^ PC) to observe synergism with ABT-737 (BCL-2 inhibition). As the number of PC is already strongly decreased in the absence of MCL-1,^[@bib16]^ the additional impact of ABT-737 results in a \>100-fold decrease in the number of PC in both the spleen and BM ([Figure 6a](#fig6){ref-type="fig"}).

Collectively, these studies reveal the differential requirement and expression of specific anti-apoptotic BCL-2 family proteins during different stages of B-cell development ([Figure 8a](#fig8){ref-type="fig"}). It also shows that reduced expression of MCL-1 sensitizes multiple B-cell subsets to inhibition of BCL-XL or BCL-2. Recent publications shed light on the mechanism of the transient BCL-XL expression in newly generated PC, that has been described previously.^[@bib16]^ Expression of Blimp-1 represses A1, but has also been shown to bind to the *BCLX* gene promoter and promote its transcription.^[@bib30],\ [@bib31]^ Activation of XBP-1, downstream of Blimp-1, subsequently represses *BCLX* ([Figure 8b](#fig8){ref-type="fig"}).^[@bib31]^ The transient expression of BCL-XL is thought to safeguard PC *en route* to protective BM niches,^[@bib15],\ [@bib20]^ and we show here that BCL-XL does contribute significantly to the survival of splenic PC when MCL-1 expression is limited. The mechanism(s) that promote(s) *BCL2* transcription in Blimp-1hi PC^[@bib16]^ is currently unresolved. Our results suggest that combining inhibition of BCL-2 with drugs that reduce the expression or activity of MCL-1 may prove valuable for targeting auto-reactive or malignant PC in autoimmune disease or multiple myeloma, respectively.

Materials and Methods
=====================

Mice
----

C57BL/6 mice, *Prdm1*^GFP/+^ mice,^[@bib23]^ *Mcl1*^flox^ mice,^[@bib16]^ *Bclx*^flox^ mice,^[@bib16]^ Rosa26-Cre^ERT2^ (hereafter, called Cre^ERT2^) mice^[@bib16]^ (Taconic Artemis, Hudson, NY, USA) and *μ*MT-deficient mice^[@bib32]^ were bred and maintained at the animal facilities of the Walter and Eliza Hall Institute (WEHI). All gene-targeted mice were maintained on a C57BL/6 background. *Bcma*^−/−^ mice^[@bib16]^ were on a C57BL/6-and-C3H/He mixed genetic background. All animal procedures were approved by the WEHI Animal Ethics Committee. BM-reconstituted mice were generated as described.^[@bib16]^ In brief, lethally irradiated C57BL/6 (Ly5.1^+^) mice were reconstituted with 80% B-cell-deficient (*μ*MT) BM plus 20% of either (Ly5.2^+^) Cre^ERT2^, *Mcl1*^fl/+^Cre^ERT2^, *Mcl1*^fl/fl^Cre^ERT2^, *Bclx*^fl/fl^Cre^ERT2^ or *Mcl1*^fl/+^*Bclx*^fl/fl^Cre^ERT2^ BM. Activation of the Cre^ERT2^ conditional recombinase to achieve deletion of *lox*P-flanked *Mcl1* or *Bclx* alleles was performed by oral gavage of tamoxifen on 2 successive days, as described.^[@bib16]^ Alternatively, mice deficient for BCMA were generated by reconstitution of lethally irradiated C57BL/6 (Ly5.1^+^) mice with 100% *Bcma*^−/−^ BM (Ly5.2^+^). ABT-737 (Abbott Laboratories, Abbott Park, IL, USA) or vehicle control were prepared and administered at 75 mg/kg body weight for 5 consecutive days as described.^[@bib19]^

Flow cytometry
--------------

Single-cell suspensions were stained with the following fluorochrome-conjugated monoclonal antibodies: anti-B220 (RA3-6B2), anti-IgM (331.12), anti-IgD (11.26C), anti-CD23 (B3B4), anti-CD21 (7E9), anti-Fc*γ*R (2.4G2), anti-human CD4 (OKT4) all produced in-house, anti-CD138 (281.2; BD Biosciences, San Jose, CA, USA) and anti-CD45.2 (104; BD Biosciences). Stained cells were analyzed on a FACSCanto II cytometer (BD Biosciences). B-cell populations were sorted from spleen and BM using a MoFlo cytometer (DAKO Cytomation Ltd, Ely, UK) to a purity of 98%.

Quantitative PCR
----------------

RNA isolation, quantitative real time PCR and primer sequences are as described.^[@bib15],\ [@bib16]^

BH3-mimetics and apoptosis assays
---------------------------------

Single-cell suspensions from the spleen or BM were cultured with A-1210477 (catalog number CT-A121, ChemieTek, Indianapolis, IN, USA) at a concentration range of 0, 1, 5 or 20 μM, A-1155463 (catalog number CT-A115, ChemieTek) at 0, 10, 100 or 100 nM, or ABT-199 (catalog number A0776, LKT Laboratories, St Paul, MN, USA) at 0, 10, 100 or 1000 nM for 20 h at 37ºC. Cell viability after treatment was assessed by flow cytometry using the TO-PRO-3 dye (catalog number T3605, ThermoFisher, Waltham, MA, USA) after gating on specific B-cell subsets using the gating strategy as shown in [Figures 1a and b](#fig1){ref-type="fig"} or as previously published for PC.^[@bib16]^ Specific apoptosis was calculated by measuring the altered percentage of TOPRO3^−^ (live) cells within indicated B-cell populations, compared with untreated cells. LC50 values were subsequently calculated using Excel and Graphpad Prism software, and specific apoptosis values after incubation with a concentration range of the inhibitors.

Statistical analysis
--------------------

Statistical significance was determined using a Mann--Whitney test when comparing two groups of mice ([Figures 2a, c](#fig2){ref-type="fig"},[4a, c, d](#fig4){ref-type="fig"},[5](#fig5){ref-type="fig"} and [6a](#fig6){ref-type="fig"}), or a Kruskal--Wallis test followed by a *post hoc*Dunn\'s multiple comparisons test in case multiple groups of mice or cell subsets were compared ([Figures 1c](#fig1){ref-type="fig"} and [3](#fig3){ref-type="fig"}).
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![B-lymphoid cells are reliant on MCL-1 expression throughout development. (**a** and **b**) Flow cytometric analysis of cells from the BM and spleen of a control (*Mcl1*^+/+^ER^T2^Cre) mixed-BM chimeric mouse. (**a**) Subset representation in the BM. Abbreviations adjacent to outlined areas indicate the corresponding B-cell population with immature (Imm; B220^+^IgM^+^IgD^−^), transitional (T; B220^+^IgM^hi^IgD^int^) or recirculating mature (Re; B220^+^IgM^int^IgD^hi^) B cells in BM. (**b**) Subset representation in the spleen. Abbreviations adjacent to outlined areas indicate the corresponding B-cell population with transitional type 1 (T1; CD23^−^IgM^+^CD21^lo^), transitional type 2 (T2; CD23^+^IgM^hi^CD21^hi^), marginal zone (MZ; CD23^−^IgM^hi^CD21^hi^) or mature follicular (Fo; CD23^+^IgM^+^CD21^+^) B cells. (**c**) Absolute numbers of B-cell populations from the BM and spleen of mixed-BM chimeras after induced deletion of one (*fl/+*) or two (*fl/fl*) alleles of *Mcl1*. *In vivo* Cre-mediated gene deletion was induced by two tamoxifen treatments on consecutive days by oral gavage, with mice sacrificed 48 h after the first dose. Cell numbers were calculated based on total cell numbers per organ and gates of dot plots from flow cytometric analysis as shown in (**a**) or (**b**). Efficiency of *Mcl1* gene deletion was shown previously.^[@bib15]^ Data represent two independent experiments and six or seven animals per group. (**d**) Fold reduction of B-cell numbers throughout development comparing control *Mcl1*^+/+^ER^T2^Cre to *Mcl1*^fl/fl^ER^T2^Cre mixed-BM chimeras, based on numbers shown in (**c**) and on previously published data.^[@bib16]^ \**P*⩽0.05, \*\**P*⩽0.01, \*\*\**P*⩽0.001 (statistical significance was calculated between the groups using a Kruskal--Wallis test followed by a *post hoc* Dunn\'s multiple comparisons test)](cddis2016237f1){#fig1}

![Reduced expression of MCL-1 sensitizes B cells to deletion of *Bclx*. (**a**) Absolute numbers of cells from the spleen and BM of mixed-BM chimeras after induced deletion of both (*fl/fl*) alleles of *Bclx* calculated as in [Figure 1](#fig1){ref-type="fig"}. *In vivo* Cre-mediated gene deletion was induced by two tamoxifen treatments on consecutive days by oral gavage, with mice killed 4 days after the first dose. This longer interval allowed for the loss of BCL-XL protein, which has a longer half-life (\~24 h) than MCL-1 (\<1 h).^[@bib15]^ Efficiency of *Bclx* gene deletion was shown previously.^[@bib16]^ Data represent two independent experiments and six animals per group. (**b**) Fold reduction of B-cell numbers throughout development comparing control *Bclx*^+/+^ER^T2^Cre and *Bclx*^fl/fl^ER^T2^Cre mixed-BM chimaeras, based on numbers shown in (**a**). (**c**) Absolute numbers of cells after induced deletion of one (*fl/+*) allele of *Mcl1* and both (*fl/fl*) alleles of *Bclx*. Mice were killed 4 days after the first tamoxifen treatment. Data represent three independent experiments and 10--15 animals per group. (**d**) Fold reduction of B-cell numbers comparing *Mcl1*^fl/+^*Bclx*^+/+^ER^T2^Cre and *Mcl1*^fl/+^*Bclx*^fl/fl^ER^T2^Cre mixed-BM chimeras, based on numbers shown in (**c**). \**P*⩽0.05, \*\**P*⩽0.01, \*\*\**P*⩽0.001 (statistical significance was calculated between the groups using a Mann--Whitney test)](cddis2016237f2){#fig2}

![Gene expression of *Mcl1*, *Bcl2*, *Bclx (Bcl2l1)* and *A1 (Bcl2a1)* throughout B-cell development. Quantitative PCR analysis of mRNA encoding pro-survival members of the BCL-2 family in different B-cell populations. FACS-sorting was performed as shown in [Figures 1a and b](#fig1){ref-type="fig"}. Data are normalized to expression of the housekeeping gene *Hprt* and presented relative to expression in Fo B cells, set as 0 (log~10~ of 1). Numbers in the graph indicate relative expression and represent three to five independent experiments, each performed in duplicate. \**P*⩽0.05 (statistical significance was calculated between the groups using a Kruskal--Wallis test followed by a *post hoc* Dunn\'s multiple comparisons test)](cddis2016237f3){#fig3}

![Treatment with BH3-mimetic ABT-737 reduces Blimp-1^hi^ plasma cells. (**a**) Absolute numbers of cells after treatment of wild-type mice with 75 mg/kg ABT-737 for 5 days, calculated as in [Figure 1](#fig1){ref-type="fig"}. Data represent three experiments and 7--11 animals per group. (**b**) Fold reduction of B-cell numbers comparing wild-type+vehicle and wild-type+ABT-737, based on numbers shown in (**a**). (**c--d**) Absolute numbers of Blimp-1^int^ and Blimp-1^hi^ PC after treatment of Blimp-1-GFP reporter mice (*Prdm1*^GFP^)^[@bib21]^ with ABT-737 as in (**a**). Shown are PC in spleen (**c**) and BM (**d**). Data in (**c**) and (**d**) represent two experiments and 7--8 animals per group. \**P*⩽0.05, \*\**P*⩽0.01, \*\*\**P*⩽0.001 (statistical significance was calculated between the groups using a Mann--Whitney test)](cddis2016237f4){#fig4}

![Plasma cells that persist in the absence of TNF receptor BCMA remain sensitive to ABT-737. Absolute numbers of PC (CD138^+^B220^lo^) after ABT-737 treatment of lethally irradiated mice reconstituted with *Bcma*^−/−^ BM, performed as in [Figure 4](#fig4){ref-type="fig"}. Data represent one experiment and six animals per group. \*\**P*⩽0.01 (Statistical significance was calculated between the groups using a Mann--Whitney test)](cddis2016237f5){#fig5}

![Reduced expression of MCL-1 sensitizes plasma cells to BCL-2 inhibition with ABT-737. (**a**) Absolute numbers of cells after induced deletion of both (*fl/fl*) alleles of *Mcl1* and treatment with ABT-737. Mice were killed 2 days after the first treatment with tamoxifen (treated for 2 consecutive days) and 5 days after treatment with 75 mg/kg ABT-737 (treated for 5 consecutive days). Data represent two experiments and six animals per group. (**b**) Fold reduction of B-cell numbers comparing *Mcl1*^fl/fl^ER^T2^Cre+vehicle and *Mcl1*^fl/fl^ER^T2^Cre+ABT-737, based on numbers shown in (**a**). \*\**P*⩽0.01 (statistical significance was calculated between the groups using a Mann--Whitney test)](cddis2016237f6){#fig6}

![Sensitivity of B cells to highly specific BH3-mimetics that target BCL-XL, BCL-2 or MCL-1. Response of diverse freshly isolated mouse B-cell subsets to (**a**) the BCL-XL-selective BH3-mimetic A-1155463, (**b**) the BCL-2-selective BH3-mimetic ABT-199 or (**c**) the MCL-1-selective BH3-mimetic A-1210477. Data represent cells from the spleen or bone marrow of six individual mice](cddis2016237f7){#fig7}

![Differential dependence on -- and expression of -- pro-survival BCL-2 family members throughout B-cell development. (**a**) Dependence on expression of MCL-1, BCL-2 and BCL-XL throughout B-cell development. Solid lines indicate direct reliance on indicated BCL-2 family protein based on both *in vivo* data and *ex vivo* experiments using BH3-mimetics, whereas dotted lines indicate reliance on either *in vivo* data or *ex vivo* experiments with BH3-mimetics. Data are a summary of [Figures 1c](#fig1){ref-type="fig"},[2a](#fig2){ref-type="fig"},[4a, 4c, 4d](#fig4){ref-type="fig"},[6a](#fig4){ref-type="fig"} and [7](#fig4){ref-type="fig"}. (**b**) Regulation of *Mcl1, Bcl2, Bclx (Bcl2l1)* and *A1 (Bcl2a1)* gene expression in germinal center (GC) B cells and PC. BCL-6-mediated inhibition of PC master regulator Blimp-1 can be abrogated by activation of IRF4.^[@bib33]^ This can be achieved by NF-*κ*B activation following CD40 ligation.^[@bib34]^ Activated NF-κB can promote transcription of pro-survival BCL-2 family protein A1 (BFL-1),^[@bib35]^ which is subsequently inhibited by Blimp-1 when cells differentiate to PC.^[@bib16]^ Blimp-1 can promote transcription of *Bclx,* which is subsequently repressed by XBP-1.^[@bib30],\ [@bib31]^ Expression of *Mcl1* is transcriptionally induced by stimulation of BCMA in the BM microenvironment,^[@bib16]^ however, the mechanism of increased *Mcl1* transcription in splenic PC remains unclear. Repression of *Bcl2* has been observed in the early GC but is subsequently re-expressed in mature PC,^[@bib16]^ although the upstream mediators are currently unknown](cddis2016237f8){#fig8}
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